MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) witnessed a notable upswing of 7.04% in its stock value, reaching $3.42 during the extended trading session on Wednesday. This surge contributed to the partial recovery of MIRA Pharmaceuticals stock, mitigating an 18.08% loss in the regular session and concluding at $3.20. The impetus for this positive momentum was an announcement by MIRA Pharmaceuticals heralding a paradigm shift.
In a groundbreaking revelation, MIRA Pharmaceuticals (MIRA) disclosed pioneering insights into the cognitive enhancement effects of MIRA1a in normal mice. This unveiling occurred during a presentation at the Grand Rounds of the University of Louisville’s Christine Lee Brown Envirome Institute. This significant finding was delivered by Dr. Adam Kaplin, MD, PhD, President and Chief Scientific Officer at MIRA Pharmaceuticals. He is also an Adjunct Faculty member at Johns Hopkins School of Medicine.
His presentation focused on the unique properties of THC and MIRA1a, an innovative analog of THC, which were the focus of Dr. Kaplin’s research on psychotropic drug development. The research highlighted that while THC displayed a biphasic response, being therapeutic at low doses but toxic at high doses, MIRA1a exhibited remarkable stability, even at elevated doses, without inducing any toxic side effects.
Moreover, MIRA1a demonstrated a twofold increase in the performance of normal adult mice in learning and memory tests, underscoring its potential to enhance cognitive abilities beyond conventional thresholds. The revelation of MIRA1a’s profound cognitive enhancement, evident even after a single dose, signifies a transformative breakthrough in neuropsychiatric research.
This landmark discovery solidifies MIRA Pharmaceuticals’ position at the forefront of innovative developments in psychotropic drug research. With an unwavering commitment to seizing industry-defining opportunities, MIRA Pharmaceuticals stands poised to capitalize on a vast market potential. The company concentrates its efforts on addressing anxiety and neuropathic pain within the expansive traditional neurological markets valued at over $90 billion.
According to Dr. Kaplin, cognitive impairment can be treated in a revolutionary way, especially in the early stages of dementia, according to his findings. MIRA1a has consistent therapeutic effects, even at high doses, making it a promising candidate to treat neuropsychiatric disorders.
